Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly ...

Teva Pharmaceutical Industries Ltd. ADR 0.40% $20.16B ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...

The Johns Hopkins Anticoagulation Management Service is a collaboration between the Department of Hematology and Department of Pharmacy. The service is staffed by expert physician and pharmacists who ...

Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Third Quarter 2024. At this time, all participants are in a listen-only mode. A brief question and answer session will ...

By the end of the 90s, Abbott had entered into the hematology testing market following ... York Stock Exchange on the 2nd January under the symbol "ABBV". "We wish our colleagues at AbbVie ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September ...

Purpose: The chemical interactions that cause drug incompatibility in solutions, with emphasis on the acid-base and ionized-nonionized forms of organic, weak, electrolyte drugs, are examined ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsLarry Heaton – Chief Executive OfficerMike ...

CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the ...